Evaluation of responses to vitamin D3 (cholecalciferol) in patients on dialysis: a systematic review and meta-analysis
Xu C, Li YC, Zhao SM, Li ZX
Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 8 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Meta-analysis (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2016-04-01 · J Investig Med · vol. 64 · issue 5 · pp. 1050–1059
- Publisher
- SAGE Publishing
- Cited
- 11 citations · more than 36% of similar papers · 0.2× the field average
- References
- 38 works
- Access
- Paywalled
- Research areas
- Vitamin D Research Studies · Parathyroid Disorders and Treatments · Pharmacological Effects and Toxicity Studies
- Keywords
- Cholecalciferol, Medicine, Vitamin D and neurology, Internal medicine, Placebo, Parathyroid hormone, Calcitriol, Dialysis, vitamin D deficiency, Hemodialysis, Kidney disease, Vitamin, Endocrinology, Gastroenterology, Calcium
- MeSH
- humans, calcium, phosphorus, cholecalciferol, parathyroid hormone, renal dialysis, sensitivity and specificity, publication bias, outcome assessment, health care
4 authors
From CN
- Xu ChenCapital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Yanchun LiCapital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Sumei ZhaoCapital Medical University; Beijing Chao-Yang Hospital, Capital Medical University
- Zhongxin Li · correspondingBeijing Luhe Hospital Affiliated to Capital Medical University
Abstract
Vitamin D plays a key role in mineral metabolism and its deficiency is often noted in patients on dialysis for end-stage renal disease (ESRD). We evaluated the efficacy and responses to vitamin D3 (cholecalciferol) in patients undergoing dialysis for ESRD. Randomized controlled trials or prospective studies comparing vitamin D3 supplementation to placebo in patients with ESRD on dialysis were searched from medical databases using the terms, 'Calcitriol/Cholecalciferol, vitamin D, chronic kidney disease, hemodialysis, serum calcium, parathyroid hormones (PTH), phosphorus, 25(OH)D, and 1,25(OH)2D'. The outcomes analyzed were serum calcium, PTH, phosphorus, 25(OH)D, and 1,25(OH) 2D levels. Of the 259 records identified, 9 studies with a total of 368 patients were chosen for the current meta-analysis. The number of patients, age, and gender distribution among the groups were comparable. Results reveal a greater increase in both 25(OH)D (Pooled difference in means=0.434, 95% CI 0.174 to 0.694, p=0.001) and 1,25(OH) 2D (Pooled difference in means=0.978, 95% CI 0.615 to 1.34, p<0.001) in the treatment arm, as compared to the placebo. There was no difference in the serum calcium or PTH among the two groups. However, patients in the treatment arm had a significant increase in phosphorus levels (Pooled difference in means=0.434, 95% CI 0.174 to 0.694, p=0.001). Vitamin D supplementation facilitated the maintenance of increased levels of 25(OH) D and 1,25(OH) 2D in patients undergoing dialysis for ESRD. This increase in vitamin D was not associated with hypercalcemia or significant changes in PTH levels.
Abstract via Europe PMC. Copyright remains with the authors or publisher.
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.